According to a couple of studies, taking Avastin before undergoing a breast cancer surgery could help reduce the risks to the patients significantly as it shrink tumors and reduce the chance of recurrence in patients.

Avastin is suited in women with less common but more aggressive forms of breast cancer, said the two studies published in the New England Journal of Medicine on Wednesday. The studies indicated that the medicine would be helpful for patients with earlier stages of breast cancer before undergoing surgery.

The first study in Europe found that patients with triple negative breast cancer had 11 percent greater chance of having their tumor completely disappear if get received Avastin with standard therapy compared to those who did not receive Avastin with standard therapy.

The second study that was undertaken in North America shows that such patients are 6 percent more likely to have their tumor completely disappear compared with those who did not receive Avastin with standard therapy. The study also found benefits of Avastin in women with a less aggressive form of breast cancer.

The FDA revoked its approval of Avastin for use in metastatic breast cancer patients in November 2011 as it was unknown which type of patients it helps and as there was no evidence that the benefits of the drug outweigh the risks.